Sanofi has entered into a collaboration agreement with Kali Therapeutics to obtain exclusive worldwide rights to KT501, a novel tri-specific T cell engager designed for autoimmune conditions. The drug candidate was discovered using Kali's proprietary discovery and research platform and represents Sanofi's continued push into the autoimmune therapeutic space.
KT501 is an Immunoglobulin G (IgG)-like tri-specific T cell engager engineered to bind CD3, CD19, and BCMA with high affinity. This multi-target approach is designed to engage a broad range of B cell populations, potentially offering advantages over single-target therapies in autoimmune disorders where B cell dysregulation plays a central role.
The collaboration carries a total potential value of up to $1.23 billion, though specific details about upfront payments, milestones, and regulatory timelines were not disclosed in available sources. The deal structure and clinical development pathway for KT501 remain to be detailed as the partnership moves forward.
For Sanofi, this acquisition strengthens its autoimmune portfolio and provides access to Kali's specialized T cell engager technology platform. The pharmaceutical industry has shown increasing interest in multi-specific antibody formats as potential next-generation treatments for complex autoimmune conditions where traditional approaches have shown limited success.